INTRODUCTION
Systemic candidiasis has been recognized as an important infectious complication in patients with myeloproliferative (1) (2) (3) (4) (5) and solid organ tumors (2, 5) , in immunosuppressed transplant recipients (6) , and in patients during the postoperative period (5, 7) . The antemortem diagnosis of systemic candidiasis is difficult to establish (1) (2) (3) (4) (5) (6) (7) because the clinical presentation is usually nonspecific and the microbiologic diagnosis is often difficult to obtain. Deep Candida infection without documented candidemia occurs 28-64% of the time in re-eight cases fulfilling the criteria, four had positive blood cultures for Candida drawn on Deep Canidida infection could not be excluded in two patienits (J. H. and H. C.). They were treated for 10-15 days with antifungal chemotherapy but died f rom other causes without pathologic evidence at autopsy of Candida infection. They are identified as possible cases of systemic candidiasis.
Invasive gastrointestinal candidiasis (2) was diagnosed histologically in tissue obtained from autopsy (four cases) or surgical pathology (one case).
Superficial Candida infections were diagnosed by clinical appearance with confirmatory culture and stain and (or) biopsy of specimens from the skin, oropharynx, vagina, surgical wound, or urinary bladder. In no case was evidence for deel) organ infectioni present and in n1o case was systemic therapy required.
Candida colonization was (listinguished from superficial or systemic infection by the total absence of clinical or histologic manifestations of infectioni, altlhough Candida was cultured from nondiagnostic sources listed above. Fungi were isolated from clinical and pathologic specimens and identified using standard techniques (19) in the North Carolina Memorial Hospital Mycology Laboratory.
Cntlti'res anid 'ucdia conditions. Candida (abicans group A (strain B311) was kindly donated by Dr Test sera were absorbed with washed sheep erythrocytes (4: 1, vol/vol) for 30 min at room temperature and 60 min at 4°C and tested with uncoated cells to assure absorption of heterophile antibody. As a control for specificity, C. albicans group A mannan was added to sera exhibiting agglutination (50 ul of mannan 2 mg/ml) to insure that hemagglutination was inhibited.
Hemagglutination inhibition (HI) assay for mannan. An HI assay was developed using immune human antiserum from patient L. F. diluted twofold below maximum agglutination titer. If a test serum was without antimannan antibody, the HI assay could be used to detect mannan antigen.
50 ml of the test sera was incubated with 50 Al of the diluted L. F. antibody and 50,ul of 0.15% suspension of sensitized sheep erythrocytes. The inhibition of hemagglutination indicated mannan antigenemia. C. albicans group A mannan either in buffer or in human serum specifically inhibited the system and was employed as a positive control.
RESULTS
Clinical findings in patients with systemic candidiasis. The clinical and pathologic data on the 14 cases of systemic candidiasis are summarized in Table I courses of broad spectrum antibiotics. Additional predisposing features included treatment with corticosteroids in five cases, and cytotoxic chemotherapy in one case. In 11 cases (79%,-), the diagnosis was clinically suspected and antifungal chemotherapy and(or) drainage initiated. However, systemic fungal disease was the primary or major contributing cause of death in eight cases. Of those wvho died, three patients received no systemic aantiftingal chemotherapy and four patients received inadequate courses. In the latter group, specific antifungal chemotherapy was initiated preterminally. Disseminated Canidida infection was documented in 5 of 10 cases coming to autopsy.
Clini.ical finidings in patients wuith sutper>ficial Candida infections or with colonization with Canzdida. The ages of the 38 subjects in these control groups ranged from 18 to 84 yr with a mean age of 52 yr. Associated or underlying conditions included myeloproliferative or solid organ tumors (11 cases), postoperative state (7 cases), systemic collagen vascular disease (7 cases), diabetes mellitus (5 cases), severe burn (2 cases), and bacterial sepsis (18 cases). 14 patients were anergic and 6 leukopenic. Additional predisposing features included broad spectrum antibiotic therapy in 31 cases, cytotoxic chemotherapy or irradiation in 12 cases, corticosteroid therapy in 6 cases, and intravenous hyperalimentation in 6 cases.
Precipitins to "S" antigen. In rabbits immunized with "S" antigen, specificity for at least 15 separate antigens from C. albicans was identified in individual bleedings from six different animals (Fig. 1) . In contrast, the initial humoral immune response was directed toward the cell-surface polysaccharide mannan in sera from five patients with systemic candidiasis. On immunoelectrophoresis. C. albicans group A mannan was found to migrate cathodally to yield a characteristic precipitin arc which was the major precipitin arc developed by human sera containing antibody to crude "S" antigen. Precipitins to "S" antigen were detected in 9 of 14 patients with systemic candidiasis (Table II) Numbers in parentheses refer to the percentages in their respective columns.
* Titer expressed as the log2.
Includes two cases of systemic aspergillosis, three of blastomycosis, three of cryptococcosis, one of acute histoplasmosis, and one of mucormycosis.
by disseminated Candida infection. Precipitins to "S" antigen could be detected in control populations without systemic Candida infection, in 4 of 20 patients with superficial Candida infections, and in 2 of 18 patients colonized with Candida (Table III) .
Antimannan antibody detected by passive hemagglutination. Passive hemagglutination of sheep cells coated with mannan proved to be a sensitive test for the detection of antimannan antibody. Mannan antibodes were detected by passive hemagglutination earlier in the clinical course than by precipitins, and were detected in all 14 patients with systemic candidiasis and in 4 of 5 patients with invasive gastrointestinal candidiasis (Table III) . They were not detected in 28 sera from six patients with invasive Candida infections who exhibited mannan antigenemia. At least a 4-fold rise in antibody titer occurred in 10 of 12 patients with systemic candidiasis who were followed serially; a 264-66,000-fold increase in titer was observed in 5 patients. Among the control groups, mannan antibody was almost universally detected (Table III). The mean maximum titers of the patients with systemic candidiasis and with candidemia associated with intravenous catheters were higher than other groups studied, although overlap in antibody titer in individuals of different groups occurred. Maximum increases of 264-fold in antibody titer were documented in serial sera from patients with transient candidemia associated with infected intravenous catheters and patients with superficial Candida infections.
Mannan characterized by the HI assay. C. albicans group A mannan run on a linear 10-40% sucrose density gradient was detected by the HI assay in a broad spectrum of molecular weights from 150,000 to 900,000.
By the technique of single radial immunodiffusion, with rabbit antibody or antibody from L. F., a minimum concentration of 150,ug/ml of mannan was detectable. However with the HI assay, 0.3 ,ug/ml of C. albicans group A mannan could routinely be detected. Mannans trols. Sera from two normal subjects with low antimannan antibody titer was unaffected by a-mannosidase treatment. Recovery of mannan antibody from purified immune precipitates was enhanced by a-mannosidase treatment. Finally, a-mannosidase by itself did not cause nonspecific agglutination of mannan sensitized erythrocyes.
Serum from patient L. F., which contained a high titer antimannan antibody and was used extensively in the HI assay, was initially studied by quantitative precipitin techniques using C. albicans group A mannan (Fig. 2) . At equivalence 200 ,ug mannan precipitated 820 Ag antimannan antibody per 0.5 ml heat inactivated serum. A linear relationship of antibody vs. concentration of antigen was noted in immune precipitates in the zone of antibody excess. Antibody and antigen could be readily detected in supernates in the zones of antibody and antigen excesses by PH and HI respectively. Soluble complexes could not be detected by the Clq precipitin assay in the zone of antigen excess.
Mannan antigenemia in invasive candidiasis. A total of 305 patients were studied (Tables II-III) . With the HI assay, mannan antigenemia was documented early in the course of 4 of 14 patients with systemic candidiasis (Table II) . Of these 14 cases, 8 were proved to have systemic infections by histologic criteria and in 2 of these 8 patients, antigenemia was detected. Four patients were diagnosed as having systemic candidiasis from positive antemortem cultures (histopathology unavailable). Antigenemia was detected in two of these cases. In the two patients with possible systemic candidiasis, antigenemia was not detected.
Fungemia was detected in only one of the four patients with antigenemia, although a minimum of six blood cultures were drawn in each case. In those patients in whom antifungal chemotherapy was started, blood cultures were drawn before treatment. Mannan was present in three patients up to 10 days before the development of precipitins to Candida cytoplasmic or cell wall antigens. After intervals of 1-6 days, antigenemia cleared, and mannan antibody was detected in rising titers. All 14 patients with systemic candidiasis developed antimannan antibody detected by passive hemagglutination. The 10 patients who were antigen negative were positive at the outset for mannan antibody.
Mannan was also detected in sera from two of five patients with invasive gastrointestinal candidiasis (Table III). In these two cases, more extensive gastrointestinal involvement was found at autopsy: multiple extensive ulcerations of stomach, and small and large intestines with pseudohyphae extending into the muscular layer were found in one case; and ulcerative esophagitis in the second.
Mannan was not detected, however, in sera from 20 patients with superficial Candida infections, 18 IUustrative case. Patient L. F. (Table IV) . A 55-yrold female was transferred from another hospital because of acute renal failure, severe metabolic acidosis, and depressed sensorium. On hospital day 2 at the end of a 36-h peritoneal dialysis, the peritoneal fluid return was yellow and cloudy. Physical examination demonstrated abdominal signs of peritonitis. Gram stain and KOH preparations demonstrated yeast forms from urine, sputum and peritoneal fluid obtained both from the peritoneal dialysis catheter and by separate paracentesis. The patient was treated with 1.5 g of 5-fluorocytosine that evening. On the 3rd hospital day, 5 mg of amphotericin B was infused intraperitoneally, followed by 5 mg intravenously. Nystatin was given orally. Over the next 6 days, 120 mg of amphotericin B was given parenterally. Cultures were later reported-to have grown C. -tropicalis from three peritoneal fluid specimens, from a tracheal aspirate, and from urine. Eight blood cultures taken over the first 3 days were sterile. The patient clinically improved with return of renal function and resolution of peritonitis. She was discharged on the 20th hospital day. Follow-up examinations to the .20th month have failed to demonstrate recurrent fungal infection.
Prospectively, serum precipitins to "S" antigen were not demonstrated until the 10th hospital day. Retrospective testing documented mannan antigenemia in seven different sera over the first 5 hospital days. After antifungal chemotherapy was started, mannan disappeared from the serum. Antimannan antibody detected by passive hemagglutination appeared on the 6th hospital day and by the 14th hospital day reached a titer of 1: 66,000. Serum precipitins were not detected until 10 days after the first demonstration of serum mannan, 7 days after the patient was first treated with antifungal chemotherapy, and 4 days after the patient had clinically improved. DISCUSSION The difficulties of diagnosis and treatment of systemic Candida infection prompted this investigation (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) To test the HI assay for specificity for mannan, sera obtained from patients at the time of invasive Candida infections were treated with an a-mannosidase which hydrolyzes mannose from natural a-mannoside carbohydrates and glycoproteins. Treatment of these sera resulted in disappearance of mannan from serum, and either recovery or increased activity of mannan antibody.
The HI assay was evaluated by correlating mannan antigenemia with clinical events during the course of systemic infection. In this way, early in the course of disease, before the appearance of precipitins to "S" antigen, mannan antigenemia was documented in 4 of 14 patients with systemic candidiasis and 2 of 5 patients with invasive gastrointestinal candidiasis. Notably, in three patients with mannan antigenemia and systemic Canidida infections, fungemia could not be documented in blood cultures. After 1-6 days, antigenemia cleared with or without antifungal chemotherapy, and mannan antibody appeared in rising titer. In two patients with invasive gastrointestinal candidiasis, the detection of mannan antigenemia suggested absorption of mannan from ulcerated visceral lesions. The detection of antibodies to "S" antigen late in the clinical course generally correlated with high titer mannan antibody detected by passive hemagglutination. The presence of mannan antigenemia was compared in patients with systemic infection and in control groups; mannan was not found in patients with superficial Candida infections, colonization, or other mycotic infections, and it was detected in low titer in only 1% of 234 normal blood donors and other hospital patients. Thus, the HI assay for serum mannan permitted early, specific serologic detection of invasive Candida infection in 30% of the infected patients.
A report by Miller et al. (36) , supports the concept of mannan antigenemia in Candida infections. Using gas-liquid chromatography, the authors identified abnormal chromatograms in six patients with candidemia and in two of four patients with invasive Candida infections. Co-chromatography studies suggested that the abnormal peaks could be derivitives of mannose.
A sensitive passive hemagglutination assay for antimannan antibody was also tested for its value in the diagnosis of systemic candidiasis. Antimannan antibody was found to be ubiquitous in patient and control populations. Antibody titers did not discriminate between noninvasive and systemic infection for, although titers were generally higher in patients withl systemic disease, they overlapped with control groups. Also, changes in titer were not prognostic of clinical outcome or response to therapy. Rising titers could generally be detected before precipitins to "S" antigen. Similar observations have been made regarding serum agglutinins to nonviable Candida cells (13) (14) (15) .
In the present study, precipitins to "S" antigen were detected relatively late in the course of systemic Candida infection, and were also present in 6 
